“Initiatives towards Sustainable Growth”
“Integration of Assets Acquired in FY 2016”

Terumo Corporation
President and CEO
Shinjiro Sato

November 9, 2017
Key Initiatives towards Sustainable Growth

- Strengthen Global Operations
- Accelerate Strategic Development
- Leverage Group’s Comprehensive Strength
Strengthen Global Operations

- Strengthen production capacity in growing arena
  - TIS*: Yamaguchi, Vietnam (Hanoi), MV: Southern CA, Costa Rica, Alliance: Yamaguchi

- Optimize production among TIS factories on a global basis
  - Promote integration of closure device production (Puerto Rico, US, Costa Rica)
  - Expand production base in US for peripheral intervention products
  - Realign production portfolio and increase the number of engineers at Ashitaka factory

- Optimize production on a global and group basis
  - Promote to mutually utilize space and technology among factories/companies
  - Hold first “Global Production Management Meeting” beyond the frame of each company

- Quality management system accommodating US-FDA well secured a foothold among the entire group
  - In 1H, FDA inspected five factories and completed them with no major observations (Cardiac and Vascular 3, General Hospital 1, Blood Management 1)
  - Among the above, the first inspection post lift of CD* at Ann Arbor factory, US also completed with no major observations (Sep)

*TIS: Terumo Interventional Systems, MV: MicroVention, CD: Consent Decree
Accelerate Strategic Development

- Formed new organization “Corporate R&D Center” at Shonan Center
- Opened “MicroVention Worldwide Innovation Center” in Southern CA, US
- Establish “TIS Mastery Center” at Ashitaka Factory
- Expand the R&D base in Southern CA: Lab to incubate in-house early technologies
- Enhance product and system portfolio for regenerative medicine and immunotherapy
- Accelerate innovative R&D after M&A
  - WEB from Sequent Medical (become the first player launching a new type of aneurysm embolization system into US)
  - Vado from Kalila Medical (expand the product portfolio of steerable sheath for ablation)
  - TAA stent graft from Bolton Medical (develop pipeline following existing products)
Leverage Group’s Comprehensive Strength

- New product development and sales expansion through collaboration among companies
  - Expand sales for carotid artery stent system “Roadsaver” and peripheral embolization coil “AZUR”
  - Reinforce the product line-up for interventional oncology (bioresorbable drug-eluting beads)
  - Stay on track for clinical trial of peripheral drug coated balloon “Kanshas”, expecting to launch within FY17

- Rotation of human resource beyond the frame of organization and company
  - Japan: Cross-rotation of company’s sales force between Cardiac and Vascular and General Hospital

- Promote collaborative initiatives among companies (R&D, Production, Sales)

- Invigorate global meetings led by CXO: cross-organizational activities are in full swing in Terumo group

- Initiate disease-oriented projects beyond the frame of each company
  - Cancer, Regenerative/Cell therapy, Foot care (Diabetic foot problem), Surgery and others
Integration of Assets acquired in FY 2016
Successful Track Record of M&A

M&As in US and Europe are the Main Drivers of Sales Growth

Sales in BJOR

- Bolton (US) Mar, FY16
- Angio-Seal (US) Jan, FY16
- Sequent (US) Jun, FY16
- Fogarty Venture Fund (US)
- Harvest (US)
- CaridianBCT (US)
- MicroVention (US)
- Vascutek (U.K.)
- Cardiovascular Div. of 3M (US)

CAGR (FY99-FY16): 7%

M&A: 30%

Organic growth: 70%

© Terumo Corporation 2017/11/9
Evolution on Integration Know-how

The First Phase (-2006)
- Acquired completely new technology Terumo never owned before (Heart-lung machine, vascular graft, neurovascular embolization coil, and others)
- Retained existing management team and kept the acquired company as a subsidiary
- Principles of autonomous management

- Acquired the company in the arena where Terumo also had business (Blood Transfusion)
- Reverse integration: Merged Terumo business into the acquired one
- Designated TBCT’s president Mr. Perez as a member of BOD of the Group. Positioned TBCT as a global HQs of Blood Management Company

The Tertiary Phase (2016-)
- Conducted three M&As in a year (+10 BJPY/case)
- Integrate acquired assets into existing overseas entities and manage there (Sequent→MV, Bolton→VAK*)
- Based on each circumstance, select the most appropriate one from the diversified integration patterns
- Implemented large-sized acquisition (vascular closure device)

*VAK: Vascutek
Sequent Medical: Complete and Quick Integration into MV

- Decided not to hold Sequent as a entity, and integrated it completely into neurovascular business of MicroVention
- Promoted unity and invigoration of organization designating Sequent’s key persons as executives of MicroVention (e.g. R&D, Clinical Development)

Current Status

- Has expanded sales territory and shown strong sales
- After acquisition, widened the application of WEB by adding smaller size into line-up
- Clinical development has been proceeding well toward US approval in FY19
Closure Devices: Integrated into Operation in TIS, US

- Asset acquisition: existing sales force specialized for access devices sells closure devices under TIS in US
- Improve customers satisfaction by TIS’s specialty “training and education” coupled with products modification

Current Status

- Sales surpassed the plan by increasing number of customer accounts in US
- Factory in Puerto Rico: Integration was on track...
  - Damages to the exterior by hurricane are limited
  - Partially resume production owing to generator in place
  - Electricity supply resumed on Nov 5, yet it is still unstable

Strive to release products within Dec, 2017

- For mid-term period, optimize production system through combining Maryland factory, US

- Maximized complementary both in region-wise and product-wise. Incorporated Bolton into vascular graft business in Vascutek

<table>
<thead>
<tr>
<th>Stent Graft</th>
<th>TAA</th>
<th>AAA</th>
<th>Vascular Graft and others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolton Medical</td>
<td>B</td>
<td>B</td>
<td>V</td>
</tr>
<tr>
<td>VASCUTEK</td>
<td>B</td>
<td>V</td>
<td>V</td>
</tr>
<tr>
<td>VASCUTEK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TERUMO</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Current Status**

- Good momentum mainly in sales of TAA stent graft “RELAY PLUS”
- Structuring sales force specialized for stent graft, capable of training as well as clinical development activities
- Japan: have both TAA and AAA stent grafts in product line-up, and start direct sales from FY19
Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

The market share information in this presentation is partly derived from our own independent research.